NFL-301
Excessive Alcohol Consumption
Pre-clinicalActive
Key Facts
About NFL Biosciences
NFL Biosciences is a clinical-stage biotech focused on botanical drug candidates for substance addictions, including tobacco, alcohol, and cannabis. Its most advanced program, NFL-101 for smoking cessation, has completed three clinical studies, with a related candidate, NFL-102, also in clinical progress. The company went public in 2021, raising €14 million, and leverages a capital-efficient, outsourced research model while holding five patent families to protect its innovative approach.
View full company profile